The FDA is considering allowing seven unapproved peptides—substantially sourced through a Chinese gray market—to be used by U.S. compounding pharmacies, despite its own scientists warning against it. Approving them would legitimize unvetted foreign suppliers and undermine evidence-based drug regulation.
700 K Street NW, Suite 600
Washington, DC 20001
[email protected] | (202) 449-1351
| # | Наименование новости | Тональность | Информативность | Дата публикации |
|---|---|---|---|---|
| 1 | FDA issues urgent warning for energy supplements sold in gas stations that contain dangerous illegal ingredients | 0 | 6.09 | 20-04-2026 |
| 2 | Eli Lilly targets alleged black market sales of its experimental GLP-1 drug | 0 | 9.2 | 12-08-2026 |
| 3 | FDA working to close 'GRAS' food-additive loophole: What is it? | 0 | 12.78 | 10-08-2026 |
| 4 | Senators Sponsor Bill Seeking Transparency on Foreign Control in U.S. Drug Supply Chain | 0 | 8.21 | 17-07-2026 |
| 5 | NYT: администрация США может ввести ограничения на поставки лекарств из Китая | 0 | 0 | 10-09-2025 |
| 6 | WSJ: из США в Китай для борьбы с коронавирусом отправляют препараты, не прошедшие проверки | 0 | 0 | 28-01-2020 |
| 7 | Senators question whether military pharmacy program is the best deal for beneficiaries | 0 | 9.7 | 16-07-2026 |
| 8 | "Известия": Россельхознадзор предложил ввести обязательную маркировку ветпрепаратов | 0 | 0 | 22-02-2022 |
| 9 | Umary contains hidden drug ingredients | 0 | 7.95 | 07-04-2026 |
| 10 | A new case of chip smuggling shows the limits of export controls | 0 | 7 | 26-03-2026 |